Farre-Garros Roser, Lee Jen Y, Natanek S Amanda, Connolly Martin, Sayer Avan A, Patel Harnish, Cooper Cyrus, Polkey Michael I, Kemp Paul R
Molecular Medicine Section, National Heart and Lung Institute, Imperial College, South Kensington Campus, London , United Kingdom.
Medical Research Council Lifecourse Epidemiology Unit, University of Southampton, Southampton General Hospital , Southampton , United Kingdom.
J Appl Physiol (1985). 2019 Jun 1;126(6):1514-1524. doi: 10.1152/japplphysiol.00882.2018. Epub 2019 Jan 24.
Reduced physical performance reduces quality of life in patients with chronic obstructive pulmonary disease (COPD). Impaired physical performance is, in part, a consequence of reduced muscle mass and function, which is accompanied by mitochondrial dysfunction. We recently showed that miR-542-3p and miR-542-5p were elevated in a small cohort of COPD patients and more markedly in critical care patients. In mice, these microRNAs (miRNAs) promoted mitochondrial dysfunction suggesting that they would affect physical performance in patients with COPD, but we did not explore the association of these miRNAs with disease severity or physical performance further. We therefore quantified miR-542-3p/5p and mitochondrial rRNA expression in RNA extracted from quadriceps muscle of patients with COPD and determined their association with physical performance. As miR-542-3p inhibits ribosomal protein synthesis its ability to inhibit protein synthesis was also determined in vitro. Both miR-542-3p expression and -5p expression were elevated in patients with COPD (5-fold < 0.001) and the degree of elevation associated with impaired lung function (transfer capacity of the lung for CO in % and forced expiratory volume in 1 s in %) and physical performance (6-min walk distance in %). In COPD patients, the ratio of 12S rRNA to 16S rRNA was suppressed suggesting mitochondrial ribosomal stress and mitochondrial dysfunction and miR-542-3p/5p expression was inversely associated with mitochondrial gene expression and positively associated with p53 activity. miR-542-3p suppressed RPS23 expression and maximal protein synthesis in vitro. Our data show that miR-542-3p and -5p expression is elevated in COPD patients and may suppress physical performance at least in part by inhibiting mitochondrial and cytoplasmic ribosome synthesis and suppressing protein synthesis. miR-542-3p and -5p are elevated in the quadriceps muscle of patients with chronic obstructive pulmonary disease (COPD) in proportion to the severity of their lung disease. These microRNAs inhibit mitochondrial and cytoplasmic protein synthesis suggesting that they contribute to impaired exercise performance in COPD.
身体机能下降会降低慢性阻塞性肺疾病(COPD)患者的生活质量。身体机能受损部分是肌肉量和功能减少的结果,这伴随着线粒体功能障碍。我们最近发现,在一小群COPD患者中,miR-542-3p和miR-542-5p水平升高,在重症监护患者中更为明显。在小鼠中,这些微小RNA(miRNA)会促进线粒体功能障碍,这表明它们会影响COPD患者的身体机能,但我们没有进一步探究这些miRNA与疾病严重程度或身体机能之间的关联。因此,我们对从COPD患者股四头肌中提取的RNA中的miR-542-3p/5p和线粒体rRNA表达进行了定量,并确定了它们与身体机能的关联。由于miR-542-3p抑制核糖体蛋白合成能力,我们还在体外测定了其抑制蛋白合成的能力。COPD患者中miR-542-3p表达和-5p表达均升高(5倍,<0.001),升高程度与肺功能受损(肺一氧化碳转运能力百分比和第1秒用力呼气量百分比)和身体机能(6分钟步行距离百分比)相关。在COPD患者中,12S rRNA与16S rRNA的比率受到抑制,提示线粒体核糖体应激和线粒体功能障碍,且miR-542-3p/5p表达与线粒体基因表达呈负相关,与p53活性呈正相关。miR-542-3p在体外抑制RPS23表达和最大蛋白合成。我们的数据表明,COPD患者中miR-542-3p和-5p表达升高,可能至少部分通过抑制线粒体和细胞质核糖体合成以及抑制蛋白合成来抑制身体机能。慢性阻塞性肺疾病(COPD)患者股四头肌中miR-542-3p和-5p的升高与肺部疾病的严重程度成正比。这些微小RNA抑制线粒体和细胞质蛋白合成,表明它们导致了COPD患者运动能力受损。